ELTP · Elite Pharmaceuticals Inc · Metrics
$0.25
0.00 (-0.12%)
At close · Oct 21
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 13, 2026
The latest filing no longer states the doubt (first flagged Jun 29, 2026).
View the 10-Q filed Aug 13, 2026Market Cap
$268.10M
Shares
1.08B
Volume · Oct 21
223.38K
Avg daily vol (3M)
771.66K
ELTP metrics
95 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$0.25
Market cap
$268.10M
Price action
20 metricsPrice change (1W)
-1.7%
Price change (30D)
-0.8%
Price change (3M)
-33.8%
Price change (6M)
-33.8%
Price change (YTD)
-50.0%
Price change (1Y)
-59.2%
Trailing year
Price change (5Y)
+512.5%
52-week high
$0.68
52-week low
$0.22
Change from 52-week high
-64.0%
Change from 52-week low
+9.3%
Annualized volatility
55.4%
Annualized volatility (3M)
49.9%
Beta
0.6
RSI (14D)
43.6
Price vs SMA 50
-8.0%
Price vs SMA 200
-31.3%
Avg volume (3M)
771,661
Relative volume
0.3
Average dollar volume
$217,128
Company
3 metricsSector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
1.08B
Valuation
12 metricsP / E (TTM)
4.9
Trailing earnings · reciprocal yield 20.4%
PEG ratio
—
EV / revenue
1.7×
reciprocal yield 60.6%
EV / EBITDA
6.5×
reciprocal yield 15.5%
EV / EBIT
6.7×
reciprocal yield 15.0%
P / sales
1.9×
reciprocal yield 52.6%
P / book
2.6
reciprocal yield 39.1%
FCF yield
6.5%
TTM · current market cap
Buyback yield
—
P / FCF
15.3
reciprocal yield 6.5%
P / operating cash flow
14.1
reciprocal yield 7.1%
Earnings yield
21.1%
Historical valuation
8 metricsP / E historical average (3Y)
19.4×
reciprocal yield 5.2%
P / E historical average (5Y)
13.0×
reciprocal yield 7.7%
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
1.6×
reciprocal yield 62.7%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
11.0×
reciprocal yield 9.1%
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
8.3×
reciprocal yield 12.0%
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-08-14
Profitability
9 metricsGross margin
43.5%
Operating margin
24.8%
Trailing 12 months
Net margin
40.2%
Gross profit (TTM)
$61.31M
Operating profit (TTM)
$34.94M
Net income (TTM)
$56.67M
Trailing 12 months
Diluted EPS (TTM)
$0.05
FCF margin
12.4%
Effective tax rate
12.9%
Growth
11 metricsRevenue growth YoY
-19.5%
Year over year
Net income growth YoY
—
Revenue (TTM)
$141.01M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+5.6%
Year over year · more shares
Revenue CAGR (3Y)
+63.3%
Revenue CAGR (5Y)
+42.4%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
54.1%
Return on assets
40.6%
Debt / equity
0.0
Current ratio
3.8
EBITDA (TTM)
$35.99M
Free cash flow (TTM)
$17.53M
Quick ratio
3.0
Interest coverage
—
Net debt / EBITDA
-1.0
Return on invested capital
43.7%
Trailing 12 months
Net cash
$35.27M
Latest balance sheet
Cash & equivalents
$39.42M
Total assets
$139.67M
Total debt
$4.15M
Cash flow & spend
7 metricsOperating cash flow (TTM)
$19.04M
Capital expenditures (TTM)
$1.52M
R&D (TTM)
$6.10M
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
4.3%
Stock compensation / revenue
—
Ownership (13F)
9 metrics13F filers
1
13F filer change QoQ
0
Institutional ownership
0.0%
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
0.0%
Active holders' share change QoQ
+100.0%
Holder tenure
4.0
Price vs estimated holder cost
-23.0%
Ownership (registered funds)
1 metricsIndex-fund ownership
0.0%
Short interest
3 metricsShort interest
0.2%
Latest settlement · 2.2 days to cover
Days to cover
2.2d
Short-squeeze score
34 / 100
Insider activity
2 metricsNet insider buying (90D)
$34,590
Insider-sentiment score
77 / 100
Risk flags
1 metricsGoing concern
—